Home/Filings/4/0001415889-24-028839
4//SEC Filing

Johnston John Joseph 4

Accession 0001415889-24-028839

CIK 0001287098other

Filed

Dec 9, 7:00 PM ET

Accepted

Dec 10, 4:30 PM ET

Size

22.2 KB

Accession

0001415889-24-028839

Insider Transaction Report

Form 4
Period: 2024-12-06
Transactions
  • Sale

    Common Stock

    2024-12-06$3.70/sh505$1,869141,950 total
  • Exercise/Conversion

    Common Stock

    2024-12-09$2.93/sh+891$2,607142,841 total
  • Sale

    Common Stock

    2024-12-09$3.79/sh2,495$9,459141,950 total
  • Exercise/Conversion

    Common Stock

    2024-12-09$1.64/sh+1,121$1,840143,962 total
  • Exercise/Conversion

    Common Stock

    2024-12-09$2.93/sh+483$1,416144,445 total
  • Exercise/Conversion

    Common Stock

    2024-12-06$2.93/sh+505$1,478142,455 total
  • Exercise/Conversion

    Stock Option (right to buy)

    2024-12-06505891 total
    Exercise: $2.93Exp: 2027-07-14Common Stock (505 underlying)
  • Exercise/Conversion

    Stock Option (right to buy)

    2024-12-091,1210 total
    Exercise: $1.64Exp: 2030-01-20Common Stock (1,121 underlying)
  • Exercise/Conversion

    Stock Option (right to buy)

    2024-12-0948323,417 total
    Exercise: $2.93Exp: 2028-07-18Common Stock (483 underlying)
  • Exercise/Conversion

    Stock Option (right to buy)

    2024-12-098910 total
    Exercise: $2.93Exp: 2027-07-14Common Stock (891 underlying)
Footnotes (4)
  • [F1]The sales and option exercise reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2023.
  • [F2]The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.70 to $3.705, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F3]The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.705 to $3.84, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F4]This option is fully vested and exercisable.

Issuer

MAXCYTE, INC.

CIK 0001287098

Entity typeother

Related Parties

1
  • filerCIK 0001874850

Filing Metadata

Form type
4
Filed
Dec 9, 7:00 PM ET
Accepted
Dec 10, 4:30 PM ET
Size
22.2 KB